Aprepitant [Usan] en es it fr

Aprepitant [Usan] Brand names, Aprepitant [Usan] Analogs

Aprepitant [Usan] Brand Names Mixture

  • No information avaliable

Aprepitant [Usan] Chemical_Formula


Aprepitant [Usan] RX_link


Aprepitant [Usan] fda sheet

Aprepitant_[Usan] FDA

Aprepitant [Usan] msds (material safety sheet)

Aprepitant [Usan] Synthesis Reference

No information avaliable

Aprepitant [Usan] Molecular Weight

534.427 g/mol

Aprepitant [Usan] Melting Point

No information avaliable

Aprepitant [Usan] H2O Solubility

Practically insoluble

Aprepitant [Usan] State


Aprepitant [Usan] LogP


Aprepitant [Usan] Dosage Forms


Aprepitant [Usan] Indication

For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including high-dose cisplatin (in combination with other antiemetic agents).

Aprepitant [Usan] Pharmacology

Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).

Aprepitant [Usan] Absorption

The mean absolute oral bioavailability of aprepitant is approximately 60 to 65%.

Aprepitant [Usan] side effects and Toxicity

No information avaliable

Aprepitant [Usan] Patient Information

Physicians should instruct their patients to read the patient package insert before starting therapy with EMEND and to reread it each time the prescription is renewed.

Patients should be instructed to take EMEND only as prescribed. Patients should be advised to take their first dose (125 mg) of EMEND 1 hour prior to chemotherapy treatment.

EMEND may interact with some drugs including chemotherapy; therefore, patients should be advised to report to their doctor the use of any other prescription, non-prescription medication or herbal products.

Patients on chronic warfarin therapy should be instructed to have their clotting status closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of EMEND with each chemotherapy cycle.

Administration of EMEND may reduce the efficacy of hormonal contraceptives. Patients should be advised to use alternative or back-up methods of contraception during treatment with EMEND and for 1 month following the last dose of EMEND.

Aprepitant [Usan] Organisms Affected

Humans and other mammals